Clinical Trials Logo

Clinical Trial Summary

This clinical trial studies celecoxib in decreasing the damaging effects of sunburn in healthy volunteers. Celecoxib may reduce skin damage by blocking enzymes associated with sunburn in healthy volunteers.


Clinical Trial Description

PRIMARY OBJECTIVES:

I. Quantify changes in the erythema response in human subjects exposed to a range of erythemic doses of solar-simulated ultraviolet light before and after celecoxib treatment.

II. Collect blood for genetic analysis of markers likely to modulate erythema response. This includes cyclooxygenase (COX), prostaglandin receptor, P53 and excision-repair polymorphisms.

OUTLINE:

Participants undergo ultraviolet (UV)-irradiation to the right buttock at baseline, receive celecoxib orally (PO) twice daily (BID) for 10 days, and then undergo UV-irradiation to the left buttock. Chromameter readings are obtained 24 hours post UV-irradiation. ;


Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention


Related Conditions & MeSH terms


NCT number NCT02090933
Study type Interventional
Source National Cancer Institute (NCI)
Contact
Status Completed
Phase Phase 2
Start date March 2004
Completion date December 2004

See also
  Status Clinical Trial Phase
Active, not recruiting NCT01230346 - Culturally-Informed Counseling in Latinas at High Risk for Hereditary Breast or Ovarian Cancer N/A
Recruiting NCT03156309 - Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive, HER2 Negative Breast Cancer That is in Remission Phase 1
Active, not recruiting NCT02780401 - Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive, HER2 Negative Breast Cancer That is in Remission Phase 1
Completed NCT02099136 - Celecoxib in Preventing the Damaging Effects of Sunburn in Healthy Volunteers Phase 2
Completed NCT03725449 - Internet-based Intervention for Skin Self-Examination in Participants With Increased Risk for Melanoma N/A
Completed NCT01497431 - Se-Methyl-Seleno-L-Cysteine or Selenomethionine in Preventing Prostate Cancer in Healthy Participants Phase 1
Withdrawn NCT03120390 - Physical Activity in Reducing Metabolic Dysregulation (MetD) in Obese Latina Breast Cancer Survivors N/A
Terminated NCT02735512 - MDSC Clinical Assay in Finding and Monitoring Cancer Cells in Blood and Urine Samples From Patients With or Without Localized or Metastatic Bladder Cancer
Completed NCT01149096 - Collection of Bone Marrow From Donors Treated With or Without Filgrastim Phase 3
Completed NCT02961790 - Oxybutynin Chloride in Managing Hot Flashes Phase 3
Completed NCT02288416 - Video-Based Intervention in Reducing Anxiety in Patients Undergoing Lung Cancer Screening N/A
Completed NCT01698294 - Biomarkers in Post-Menopausal Women Receiving Flaxseed N/A
Completed NCT00896974 - Study of 9cUAB30 in Healthy Participants Phase 1
Terminated NCT03284346 - Exercise in Targeting Metabolic Dysregulation in Stage I-III Breast or Prostate Cancer Survivors N/A